The first substantial project of Baoshan MPI

On the morning of September 28, the starting ceremony of the Youkadi Zhizhi Life Technology Project was held in Luodian Town, Baoshan District. Chen Jie, Secretary of the Baoshan District Party Committee, Lu Dongsheng, Chairman of Guosheng's investment co -produced, and Yu Lei, chairman and chief scientist of Youkadi, attended the ceremony.

At the scene, Chen Jie announced the project.

Youkadi Zhizhi Life Technology Project is the first substantial launch project of Guoshengbao Yamana Valley. It is intended to land in the first phase of the National Shengbao Yam Valley in the North Shanghai Biomedical Industrial Park, with a construction area of ​​about 10,000 cubic meters and a total investment of 150 million yuan. The output value is about 500 million yuan.

Youkadi will build an international advanced tens of billions of genetic and cell therapy scientific research, industrialization and business centers to build a world -class immunotherapy tumor innovation technology transformation center and advanced and high -end, high -end and high -end genetic engineering immune cell industry chain centers, which mainly include The industrial production of CAR-T products and CDMO services for plasmid, virus, and CAR-T cells. Under its international first -class synthetic biological and artificial intelligence technology, Under the assistance of engineering cell therapy technology and product research and development innovation and industrialization capabilities, it adds to the development of the North Shanghai Biomedical Industrial Park in the development of cells and gene therapy. New kinetic energy.

Carrier delivery ceremony

Lu Dongsheng, Chairman of Guosheng Investment Council, delivered a speech

Yu Lei, Chairman and Chief Scientist of Youkadi, delivered a speech

Youkadi focuses on solving CAR-T clinical pain points and "clinical value". With the assistance of synthetic biology and artificial intelligence technology, it has created a new generation of unique immune cell therapy with in-depth independent innovation. Since its establishment in 2015, the company has successfully launched a number of innovative CAR-T products based on its own original original technology platform. General cell therapy products. In September 2020, Youkadi successfully obtained clinical trial permits of the world's first safe CAR-T product SSCART-19 cell injection. This product can be used for CAR-T contraindications-central nervous system leukemia The treatment is a major milestone for CAR-T therapy to treat blood tumors. In July 2022, Youkadi's independent research and development of SSCART-19 cell injection was further obtained by the US Food and Drug Administration (FDA) awarded orphan drug qualification identification (ODD), which further established the foundation of the internationalization of products.

North Shanghai Biomedical Industrial Park is located in Baoshan District, Shanghai, with a total area of ​​6.86 square kilometers. It was a "municipal biomedical characteristic industrial park" awarded by Shanghai in March 2020. In recent years, the park has successfully attracted the including Zhaohui Pharmaceutical, Baoji Pharmaceutical, Huiyong Pharmaceutical, Zhengda Tianqing Fang, Bowo Biological, Jingze Biology, Midi Si, Oriental Gene, Le Tu Technology, Meisheng Medical, etc. A batch of high -energy projects. As one of the five municipal biomedical industrial parks, North Shanghai Biomedical Industrial Park is accelerating the creation of a global influential biomedical industry cluster. The Youkadi project settled in Baoshan, showing the advantages of the park in the industrial atmosphere, innovation elements, corporate services, and park management. In the future, the park will continue to provide public services with industry characteristics, as well as competitive supporting policies and corporate ecology.

Source: Shanghai Baoshan official WeChat

- END -